Pass, Martin
AstraZeneca (United Kingdom)
2 papers on CoChat
Most cited papers
- Verified
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research
PI3K/AKT/mTOR signaling in cancerAutophagy in Disease and Therapy
Cited by 812
- Verified
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A. (2011) · Toxicologic Pathology
Immunotoxicology and immune responsesTGF-β signaling in diseases
Cited by 284
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free